Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986165 on Metformin PK in Healthy Volunteers
NCT04671953Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deucravacitinib in plaque psoriasis (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 9 days, Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration up to 9 days and 1 more. Started Dec 2020; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04671953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04671953.